Financials data is unavailable for this security.
View more
Year on year Jinyu Bio-Technology Co Ltd grew revenues 4.55% from 1.53bn to 1.60bn while net income improved 34.63% from 210.68m to 283.63m.
| Gross margin | 57.88% |
|---|---|
| Net profit margin | 17.60% |
| Operating margin | 20.19% |
| Return on assets | 3.97% |
|---|---|
| Return on equity | 5.16% |
| Return on investment | 4.64% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Jinyu Bio-Technology Co Ltd fell by 213.90m. However, the company earned 414.83m from its operations for a Cash Flow Margin of 25.96%. In addition the company generated 111.38m cash from financing while 740.11m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.81 |
|---|---|
| Tangible book value per share | 4.15 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.20 |
|---|---|
| Quick ratio | 2.80 |
| Total debt/total equity | 0.0177 |
|---|---|
| Total debt/total capital | 0.017 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 37.28%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.60% |
|---|---|
| Div growth rate (5 year) | -25.56% |
| Payout ratio (TTM) | 32.84% |
| EPS growth(5 years) | -16.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.36 |
More ▼
